Arbutus Biopharma Corporation ABUS EBITDA

EBITDA at other companies

Arrowhead ResearchARWR

-$134.89M-135%

Gilead SciencesGILD

-$10.3B-501%

ALN

Alnylam PharmaceuticalsALNY

$245.34M+10,980%

AnaptysBio, Inc.ANAB

-$34.51M-26.0%

Avalo TherapeuticsAVTX

-$31.5M-64.2%

Assembly BiosciencesASMB

-$11.34M-14.5%

FAQ

What is Arbutus Biopharma Corporation's EBITDA?

Arbutus Biopharma Corporation (ABUS) reported EBITDA of $168.92M in Q1 2026.

How has Arbutus Biopharma Corporation's EBITDA changed year-over-year?

Arbutus Biopharma Corporation's EBITDA increased by 765.8% year-over-year, from -$25.37M to $168.92M.

What is the long-term trend for Arbutus Biopharma Corporation's EBITDA?

Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's EBITDA has grown at a -14.9% compound annual growth rate (CAGR), from -$71.76M to -$37.72M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.